Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLE

Bitget2026/09/23 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Roivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus.
Results have already been presented as topline data, showing the trial missed its main efficacy goal versus placebo.
Secondary measures showed encouraging directional signals, particularly in patients with stronger biological responses.
Development in cutaneous lupus will be halted, citing the overall readout and a competitive market backdrop.
Safety was described as favorable, with other IMVT-1402 programs kept on their existing clinical timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9832408) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLE

You may also like

Crypto prices